Bausch Health Companies BHC Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Business | ||||||
| Bausch + Lomb | $1.24B-11.5% | $1.41B+9.7% | $1.28B+0.2% | $1.28B+12.4% | $1.14B-11.2% | |
| Diversified | $185M-27.5% | $255M-1.2% | $258M+17.8% | $219M+6.8% | $205M-10.1% | |
| International | $285M-6.9% | $306M+7.0% | $286M+2.9% | $278M+6.1% | $262M-6.1% | |
| Salix | $639M-7.8% | $693M-3.2% | $716M+14.2% | $627M+15.7% | $542M-14.5% | |
| Solta Medical | $171M+24.8% | $137M-2.1% | $140M+9.4% | $128M+13.3% | $113M-18.1% | |
| Operating Income (Loss) by Business | ||||||
| Bausch + Lomb | $277M-30.1% | $396M+31.6% | $301M+21.4% | $248M+37.8% | $180M-41.7% | |
| Diversified | $112M-37.4% | $179M-1.6% | $182M+30.9% | $139M+9.4% | $127M-19.1% | |
| International | $88M+8.6% | $81M-10.0% | $90M+15.4% | $78M-8.2% | $85M-13.3% | |
| Salix | $468M-11.5% | $529M-7.2% | $570M+25.3% | $455M+22.6% | $371M-19.3% | |
| Solta Medical | $75M+36.4% | $55M-21.4% | $70M+29.6% | $54M+1.9% | $53M-27.4% | |
| SG&A by Business | ||||||
| Bausch + Lomb | $439M+0.7% | $436M+1.6% | $429M-8.7% | $470M+5.1% | $447M+2.5% | |
| Diversified | $43M+7.5% | $40M-2.4% | $41M-4.7% | $43M-4.4% | $45M+28.6% | |
| International | $63M-1.6% | $64M+12.3% | $57M-9.5% | $63M+21.2% | $52M+4.0% | |
| Salix | $105M+5.0% | $100M+26.6% | $79M-29.5% | $112M+0.9% | $111M+3.7% | |
| Solta Medical | $35M-12.5% | $40M+29.0% | $31M-3.1% | $32M+14.3% | $28M-15.2% | |
| R&D by Business | ||||||
| Bausch + Lomb | $45M+12.5% | $40M-2.4% | $41M+17.1% | $35M+25.0% | $28M-17.6% | |
| Diversified | $3M-25.0% | $4M+33.3% | $3M-25.0% | $4M+33.3% | $3M-25.0% | |
| International | $6M-25.0% | $8M+14.3% | $7M+16.7% | $6M0.0% | $6M-14.3% | |
| Salix | $19M-5.0% | $20M-4.8% | $21M0.0% | $21M+23.5% | $17M-26.1% | |
| Solta Medical | $8M+33.3% | $6M-33.3% | $9M+50.0% | $6M+20.0% | $5M-16.7% | |
| Additions by Business | ||||||
| Bausch + Lomb | $0-100% | $24.25M0.0% | $24.25M0.0% | $24.25M0.0% | $24.25M-10.2% | |
| Diversified | $0— | $0— | $0— | $0— | $0— | |
| International | $0— | $0— | $0— | $0— | $0— | |
| Salix | $0— | $0— | $0— | $0— | $0— | |
| Solta Medical | $0-100% | $5.5M0.0% | $5.5M0.0% | $5.5M0.0% | $5.5M— | |
| Goodwill, Foreign Currency Translation, Gain (Loss) by Business | ||||||
| Bausch + Lomb | $21M+625% | -$4M— | $0+100% | -$100M-127% | -$44M-152% | |
| Diversified | $0— | —— | —— | $18M+20.0% | $15M+154% | |
| International | $17M+270% | -$10M— | $0+100% | -$63M-70.3% | -$37M-169% | |
| Salix | $0— | $0— | $0— | $0— | $0— | |
| Solta Medical | $0— | $0— | $0— | $0— | $0— | |
| Goodwill by Business | ||||||
| Bausch + Lomb | $5.48B-0.4% | $5.5B+1.9% | $5.4B-0.2% | $5.41B+1.9% | $5.31B+0.8% | |
| Diversified | $1.58B0.0% | $1.58B-8.4% | $1.73B0.0% | $1.73B-1.0% | $1.74B-0.9% | |
| International | $880M-1.9% | $897M+0.7% | $891M-0.1% | $892M+7.6% | $829M+4.7% | |
| Salix | $1.73B-45.1% | $3.16B0.0% | $3.16B0.0% | $3.16B0.0% | $3.16B0.0% | |
| Solta Medical | $137M0.0% | $137M+19.1% | $115M0.0% | $115M0.0% | $115M0.0% | |
| Goodwill, impairment loss by Business | ||||||
| Bausch + Lomb | $0— | $0— | $0— | $0— | $0— | |
| Diversified | $0-100% | $36.25M0.0% | $36.25M0.0% | $36.25M0.0% | $36.25M— | |
| International | $0— | $0— | $0— | $0— | $0— | |
| Salix | $1.43B— | $0— | $0— | $0— | $0— | |
| Solta Medical | $0— | $0— | $0— | $0— | $0— | |
| Revenue by Product | ||||||
| Other revenues | $24M-14.3% | $28M+16.7% | $24M-7.7% | $26M-18.8% | $32M+3.2% | |
| Price Appreciation Credit | $2M-86.7% | $15M+1,400% | $1M— | $0-100% | $2M-88.9% | |
| Product sales | $2.5B-9.7% | $2.77B+4.2% | $2.66B+6.1% | $2.5B+12.4% | $2.23B-11.9% | |
| Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues by Product | ||||||
| Other revenues | $17M+13.3% | $15M0.0% | $15M-6.3% | $16M-11.1% | $18M+12.5% | |
| Product sales | $721M-7.9% | $783M+6.5% | $735M-1.7% | $748M+9.5% | $683M-3.9% | |
| Number of lawsuits pending by Geography | ||||||
| CA-BC | $1— | —— | $10.0% | $10.0% | $1— | |
| CA-QC | $1— | —— | $10.0% | $10.0% | $1— | |
| CANADA | $2— | —— | $20.0% | $20.0% | $2— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Bausch Health Companies break its business down?
- Bausch Health Companies (BHC) reports revenue by business across 5 parts — Bausch + Lomb, Diversified, International, Salix and Solta Medical. Each is extracted from the segment footnotes and tracked over time.
- Where does Bausch Health Companies's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Bausch Health Companies's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.